In the preceding three months, 6 analysts have released ratings for Moderna (NASDAQ:MRNA), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 1 | 1 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 1 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $119.17, a high estimate of $163.00, and a low estimate of $86.00. This upward trend is apparent, with the current average reflecting a 19.56% increase from the previous average price target of $99.67.
Interpreting Analyst Ratings: A Closer Look
The standing of Moderna...
Login or create a forever free account to read this news
Sign up/Log in